AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2058846
Drug: Naloxone group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone group (group N): 0.4 mg bolus followed by 5 micrograms.kg‐1.h‐1 infusion for 18 hours
Trial: 29933343
Drug: Graded Exercise
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded Exercise Therapy (GET) and Resistance Training (RT) program, 12 months duration, exercise sessions at 6 days per week, aerobic exercises with incremental training time, resistance exercises with a durable resistance band.
Trial: 27825334
Drug: Danlou tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danlou tablets
Trial: 17513394
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g avenanthramide-enriched mixture (AEM)
Trial: 17513394
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g avenanthramide-enriched mixture (AEM)
Trial: 17513394
Drug: 360 mL
RxNorm normalized name: colostomy bags 10" 360 mL MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mL skim milk (placebo)
Trial: 16156111
Drug: IV fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV fentanyl (80 microg/h) administered intermittently over 24 hours
Trial: 31472003
Drug: Preventive strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive strategy (oral calcium + vitamin D supplementation)
Trial: 31472003
Drug: Reactive strategy
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reactive strategy (therapy in hypocalcemia)
Trial: 31472003
Drug: Predictive strategy
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictive strategy (therapy if iPTH <10 pg/mL)
Trial: 28449795
Drug: Bosentan (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (target dose 125 mg twice daily)
Trial: 20933466
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (radiotherapy plus immediate androgen suppression with goserelin acetate)
Trial: 17137013
Drug: Gymnastics twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gymnastics twice a week
Trial: 12715790
Drug: Edaravone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone (30 mg, twice a day for 14 days)
Trial: 9176190
Drug: Progesterone administration
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone administration at 9:30 PM
Trial: 3058171
Drug: FUT‐175 (protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUT‐175 (protease inhibitor)
Trial: 3058171
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose heparinization (LH)
Trial: 29316946
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (Control group)
Trial: 15519187
Drug: Heparin dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin dosage of 100 iu/kg
Trial: 15519187
Drug: Heparin dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin dosage of 200 iu/kg
Trial: 15519187
Drug: Heparin dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin dosage of 250 iu/kg
Trial: 15519187
Drug: Heparin dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin dosage of 300 iu/kg
Trial: 8616834
Drug: GSTM3 AA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSTM3 AA in combination with skin type 1, GSTM1 null, and CYP1A1 m1m1
Trial: 1611985
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg midazolam, 1.5 mg/kg tramadol, 50 mg alizaprid
Trial: 1611985
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg midazolam, 0.2 mg/kg nalbuphine, 50 mg alizaprid
Trial: 4030188
Drug: Testosterone and
RxNorm normalized name: testosterone and estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone and anabolic steroids (average 57 +/- 24.9 mg/day for 6 months)
Trial: 4030188
Drug: Testosterone and
RxNorm normalized name: testosterone and estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone and anabolic steroids
Trial: 24337350
Drug: LED therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LED therapy (λ of 640 ± 20 nm and spatial average energy fluency of 1.2 J/cm(2) during hospitalization)
Trial: 24337350
Drug: LED therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LED therapy (640 nm)
Trial: 11245839
Drug: Attention-based visual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attention-based visual routines involving dynamic patterns (e.g., pairs of points in orbiting motion, 11 points in biological motion)
Trial: 9675625
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of morphine
Trial: 10381659
Drug: Calcium ointment
RxNorm normalized name: calcium undecylenate Topical Ointment
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium ointment (10% w/w calcium carbonate) applied to lower lid skin twice a day
Trial: 720774
Drug: Aspirin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (10 gm over four days)
Trial: 720774
Drug: Ibuprofen and
RxNorm normalized name: Ibuprofen and Famotidine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen and ketoprofen
Trial: 10920611
Drug: Prednisolone treatment
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone treatment
Trial: 21527597
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) plus 2 months of Tube Feeding (TF)
Trial: 15721570
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) alone
Trial: 19253241
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia (group T)
Trial: 11747472
Drug: Horse-chestnut seeds
RxNorm normalized name: horse chestnut seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horse-chestnut seeds extract (HCSE) and compression therapy
Trial: 8232429
Drug: CHVP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHVP plus interferon alfa (5 million units three times weekly for 18 months)
Trial: 25015215
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg monthly
Trial: 31718842
Drug: Ranibizumab 0.5
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.5 mg pro re nata (PRN) after 3 loading doses
Trial: 25015215
Drug: Ranibizumab 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 2.0 mg monthly
Trial: 25015215
Drug: Ranibizumab 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 2.0 mg PRN
Trial: 31718842
Drug: All ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All ranibizumab doses
Trial: 8694682
Drug: Clomipramine for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine for 9 months combined with 15 weekly sessions of brief dynamic psychotherapy
Trial: 1931397
Drug: Adenosine triphosphate
RxNorm normalized name: Adenosine triphosphate
DrugBank: ATP (DB00171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine triphosphate (ATP) 0.05 mg kg‐1 or 0.1 mg kg‐1
Trial: 6285947
Drug: Large fractions
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large fractions of radiation with high-dose metronidazole
Trial: 6285947
Drug: Radiation as
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation as in Group 2 but with equitoxic doses of MISO
Trial: 22249844
Drug: PDGF (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDGF (25 ng/ml)
Trial: 20218746
Drug: Antiparasitic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiparasitic and anti-infective drugs
Trial: 17548704
Drug: Iron intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron intake in women consuming 30+ g of alcohol per day
Trial: 17548704
Drug: Iron intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron intake in women who had ever used hormone replacement therapy
Trial: 15823510
Drug: Levetiracetam (1000-4000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (1000-4000 mg/day)
Trial: 705848
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 200 mg doxycycline
Trial: 30643398
Drug: Formoterol fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol fumarate inhalation solution (FFIS; 20 µg, n=541)
Trial: 30643398
Drug: Formoterol fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol fumarate inhalation solution (FFIS)
Trial: 23442752
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml mepivacaine 1%
Trial: 21481449
Drug: Phentermine 7.5
RxNorm normalized name: phentermine 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentermine 7.5 mg plus topiramate 46.0 mg
Trial: 21481449
Drug: Phentermine 15.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentermine 15.0 mg plus topiramate 92.0 mg
Trial: 14652086
Drug: Caffeine+Nap (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine+Nap (200 mg caffeine followed by a 20 min nap)
Trial: 11061612
Drug: Gemcitabine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine administered intravenously at 1250 mg/m2 over 30-60 minutes on days 1, 8, and 15 followed by 1 week of rest, maximum of six cycles
Trial: 8550052
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa (IFN-alpha) treatment
Trial: 29426869
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label placebo (OLP) - 2 placebo pills twice a day for 21 days
Trial: 9431710
Drug: Cow udder
RxNorm normalized name: Cow milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cow udder ointment
Trial: 27668723
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior psychophysiological therapy (CBPT)
Trial: 27668723
Drug: Music and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music and relaxation therapy (MRT)
Trial: 18940714
Drug: Peppermint and
RxNorm normalized name: BODY PRESCRIPTIONS ANTIBACTERIAL HAND SANITIZER 2 Pack PEPPERMINT and WINTER BERRY KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peppermint and neroli hydrolat spray
Trial: 18940714
Drug: Plain water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain water spray
Trial: 18940714
Drug: Both sprays
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both sprays
Trial: 16647152
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with surgery and RT at the time of LRR
Trial: 1728203
Drug: Dobutamine (0.38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine (0.38 mg/kg body weight)
Trial: 1728203
Drug: Adenosine (0.84
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (0.84 mg/kg body weight)
Trial: 1728203
Drug: Dipyridamole (0.84
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (0.84 mg/kg body weight)
Trial: 31499528
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (CEE) (0.625 mg/d)
Trial: 27091036
Drug: Helicobacter pylori
RxNorm normalized name: HELICOBACTER PYLORI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helicobacter pylori standard treatment for two weeks followed by antacid medication (morning and night) for three months
Trial: 27091036
Drug: Antacid medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid medication (morning and night) for four weeks followed by three months of antacid treatment
Trial: 25374219
Drug: Hyperglycemia group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemia group (fasting glucose≥126 mg/dl and/or random blood glucose≥200 mg/dl)
Trial: 17653959
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HRT) with 2 mg 17beta-estradiol/10 mg dydrogesterone (Femoston) for seven 28-day cycles
Trial: 16563251
Drug: Celecoxib (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (10 micromol/L)
Trial: 10087460
Drug: Theophylline (Respicur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (Respicur retard(R) 400 mg) therapy
Trial: 7754404
Drug: Intermittent cryotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent cryotherapy (standard therapy with cool packs)
Trial: 2181915
Drug: Amoxicillin +
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin + clavulanic acid (40 mg/kg/day in 3 or 4 divided doses)
Trial: 2181915
Drug: Erythromycin-sulfisoxazole (Pediazole,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin-sulfisoxazole (Pediazole, 50 mg/kg/day in 3 divided doses)
Trial: 534604
Drug: Oral candidiasis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral candidiasis
Trial: 27762489
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg thrice daily oral tranexamic acid plus HQ 4% cream nightly
Trial: 27762489
Drug: HQ 4%
RxNorm normalized name: Hydroquinone 4%
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HQ 4% cream only
Trial: 19965324
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of furosemide (Group 2, n=50, 10mg/ml)
Trial: 15347371
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (FP, 100 microg Diskus, twice daily)
Trial: 15347371
Drug: Oral montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral montelukast (MON 10 mg, nocte)
Trial: 11573668
Drug: Slow injection
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow injection of 3 ml of 0.5% plain bupivacaine by infusion pump over 3 min (1 ml min(‐1))
Trial: 11573668
Drug: Fast injection
RxNorm normalized name: Fast Freeze
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fast injection of 3 ml of 0.5% plain bupivacaine by hand over 10 s (18 ml min(‐1))
Trial: 11573668
Drug: Slow injection
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow injection group
Trial: 11573668
Drug: Fast injection
RxNorm normalized name: Fast Freeze
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fast injection group
Trial: 11041533
Drug: Zolpidem (ZPD,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem (ZPD, 10 mg)
Trial: 2201724
Drug: Triazolam (TRZ,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (TRZ, 0.25 mg)
Trial: 1862903
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine injections on demand
Trial: 6127968
Drug: Midazolam 0.1
RxNorm normalized name: midazolam 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.1 mg/kg
Trial: 6137171
Drug: Naloxone 0.015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 0.015 mg/kg
Trial: 26344009
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for GDM with diet, blood glucose monitoring, and insulin as needed.
Trial: 26344009
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for GDM with diet, blood glucose monitoring, and insulin as needed (nonobese women).
Trial: 24887209
Drug: ReNu MPS
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ReNu MPS (solution 1)
Trial: 24887209
Drug: AQuify MPS
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AQuify MPS (solution 2)
Trial: 19773417
Drug: High-dose daclizumab
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: High-dose daclizumab (first dose: 2 mg/kg) with low-dose cyclosporine (CsA), mycophenolate mofetil (MMF), and steroids
Trial: 19773417
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (CsA, MMF, steroids)
Trial: 19773417
Drug: High-dose daclizumab
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: High-dose daclizumab
Trial: 16151461
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (400 mug daily for 5 weeks)
Trial: 12162937
Drug: Alpha-tocopherol (AT)
RxNorm normalized name: alpha tocopherol
DrugBank: alpha-Tocopherol acetate (DB14003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alpha-tocopherol (AT) therapy
Trial: 10402091
Drug: Modafinil treatment
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil treatment for 9 weeks
Trial: 2147537
Drug: Amlodipine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (0.4 to 45 micrograms/min/100 ml forearm tissue)
Trial: 2147537
Drug: Amlodipine (44.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (44.5 micrograms/min/100 ml) + Verapamil (40 micrograms/min/100 ml)
Trial: 29339650
Drug: Oral Immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Immunotherapy (OIT) with a daily maintenance dose of 795 mg of peanut protein
Trial: 25823600
Drug: Oral Immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Immunotherapy (OIT)
Trial: 20369614
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with indapamide and verapamil retard
Trial: 20369614
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with indapamide and amlodipine
Trial: 10219575
Drug: Teicoplanin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (400 mg i.v. bolus at time of anesthesia)
Trial: 10219575
Drug: Cefazolin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (2 g at induction of anesthesia and 1 g every 6 h postoperatively, i.v. bolus)
Trial: 27754731
Drug: Tele‐intervention Model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tele‐intervention Model and Monitoring of Families of Drug Users (TMMFDU)
Trial: 23768273
Drug: Home physical
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home physical therapy (HPT)
Trial: 23768273
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy in conjunction with home physical therapy (MT-HPT)
Trial: 20393694
Drug: Intra-operative periarticular
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-operative periarticular injection with local anaesthetic and adrenaline plus triamcinolone acetonide
Trial: 20393694
Drug: Intra-operative periarticular
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-operative periarticular injection with local anaesthetic and adrenaline
Trial: 10589859
Drug: Heparin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin administration (1000 U, 500 U, and 500 U before exercise)
Trial: 6805451
Drug: Massive-dose vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massive-dose vitamin A therapy
Trial: 6805451
Drug: Repeated massive
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated massive vitamin A therapy